Business Context and Reporting Period
This Form 8-K Current Report was filed by BioSig Technologies, Inc. (not Streamex Corp.) on March 22, 2022, covering events occurring on March 16, 2022. The company is incorporated in Delaware and trades on the NASDAQ Capital Market under the symbol BSGM. The filing primarily addresses the appointment of a new executive officer.
Key Financial Metrics
The filing does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on executive compensation and appointment details.
Material Changes
The material change reported is the appointment of Mr. John Sieckhaus as Chief Operating Officer (COO), with employment commencing on March 21, 2022. Key compensation terms include:
- Base Salary: $280,000 annually.
- Signing Bonus: 50,000 fully vested shares of common stock.
- Stock Options: Grant of options to acquire up to 350,000 shares, vesting over three years (1/3 on the first anniversary, remainder in quarterly installments).
- Discretionary Bonus: Eligible for an annual bonus determined by the Compensation Committee.
Outlook, Risks, and Management Commentary
Management highlights Mr. Sieckhaus's 30 years of healthcare industry experience, including 21 years at St. Jude Medical and Abbott Laboratories. His background includes commercial leadership and clinical affairs, with a focus on revenue growth and team integration. The filing notes no family relationships between Mr. Sieckhaus and existing directors or officers and confirms no reportable transactions under Item 404(a) of Regulation S-K. No specific financial guidance or risk factors were disclosed in this report.
Investor Verification Checklist
- Verify the exact grant date and exercise price for the 350,000 stock options, as these depend on the trading price ten days prior to the grant.
- Review the BioSig Technologies, Inc. 2012 Equity Incentive Plan for specific terms regarding the vesting schedule and forfeiture conditions.
- Confirm the impact of the 50,000 fully vested shares on immediate dilution.
- Check subsequent filings for the actual grant date of the stock options.